Vinay Prasad1,2,3, Sham Mailankody4,5. 1. Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland. 2. Department of Preventive Medicine and Public Health, Oregon Health and Science University, Portland. 3. Center for Health Care Ethics, Oregon Health and Science University, Portland. 4. Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
Importance: A common justification for high cancer drug prices is the sizable research and development (R&D) outlay necessary to bring a drug to the US market. A recent estimate of R&D spending is $2.7 billion (2017 US dollars). However, this analysis lacks transparency and independent replication. Objective: To provide a contemporary estimate of R&D spending to develop cancer drugs. Design, Setting, and Participants: Analysis of US Securities and Exchange Commission filings for drug companies with no drugs on the US market that received approval by the US Food and Drug Administration for a cancer drug from January 1, 2006, through December 31, 2015. Cumulative R&D spending was estimated from initiation of drug development activity to date of approval. Earnings were also identified from the time of approval to the present. The study was conducted from December 10, 2016, to March 2, 2017. Main Outcomes and Measures: Median R&D spending on cancer drug development. Results: Ten companies and drugs were included in this analysis. The 10 companies had a median time to develop a drug of 7.3 years (range, 5.8-15.2 years). Five drugs (50%) received accelerated approval from the US Food and Drug Administration, and 5 (50%) received regular approval. The median cost of drug development was $648.0 million (range, $157.3 million to $1950.8 million). The median cost was $757.4 million (range, $203.6 million to $2601.7 million) for a 7% per annum cost of capital (or opportunity costs) and $793.6 million (range, $219.1 million to $2827.1 million) for a 9% opportunity costs. With a median of 4.0 years (range, 0.8-8.8 years) since approval, the total revenue from sales of these 10 drugs since approval was $67.0 billion compared with total R&D spending of $7.2 billion ($9.1 billion, including 7% opportunity costs). Conclusions and Relevance: The cost to develop a cancer drug is $648.0 million, a figure significantly lower than prior estimates. The revenue since approval is substantial (median, $1658.4 million; range, $204.1 million to $22 275.0 million). This analysis provides a transparent estimate of R&D spending on cancer drugs and has implications for the current debate on drug pricing.
Importance: A common justification for high cancer drug prices is the sizable research and development (R&D) outlay necessary to bring a drug to the US market. A recent estimate of R&D spending is $2.7 billion (2017 US dollars). However, this analysis lacks transparency and independent replication. Objective: To provide a contemporary estimate of R&D spending to develop cancer drugs. Design, Setting, and Participants: Analysis of US Securities and Exchange Commission filings for drug companies with no drugs on the US market that received approval by the US Food and Drug Administration for a cancer drug from January 1, 2006, through December 31, 2015. Cumulative R&D spending was estimated from initiation of drug development activity to date of approval. Earnings were also identified from the time of approval to the present. The study was conducted from December 10, 2016, to March 2, 2017. Main Outcomes and Measures: Median R&D spending on cancer drug development. Results: Ten companies and drugs were included in this analysis. The 10 companies had a median time to develop a drug of 7.3 years (range, 5.8-15.2 years). Five drugs (50%) received accelerated approval from the US Food and Drug Administration, and 5 (50%) received regular approval. The median cost of drug development was $648.0 million (range, $157.3 million to $1950.8 million). The median cost was $757.4 million (range, $203.6 million to $2601.7 million) for a 7% per annum cost of capital (or opportunity costs) and $793.6 million (range, $219.1 million to $2827.1 million) for a 9% opportunity costs. With a median of 4.0 years (range, 0.8-8.8 years) since approval, the total revenue from sales of these 10 drugs since approval was $67.0 billion compared with total R&D spending of $7.2 billion ($9.1 billion, including 7% opportunity costs). Conclusions and Relevance: The cost to develop a cancer drug is $648.0 million, a figure significantly lower than prior estimates. The revenue since approval is substantial (median, $1658.4 million; range, $204.1 million to $22 275.0 million). This analysis provides a transparent estimate of R&D spending on cancer drugs and has implications for the current debate on drug pricing.
Authors: Matthew Smith; Johann De Bono; Cora Sternberg; Sylvestre Le Moulec; Stéphane Oudard; Ugo De Giorgi; Michael Krainer; Andries Bergman; Wolfgang Hoelzer; Ronald De Wit; Martin Bögemann; Fred Saad; Giorgio Cruciani; Antoine Thiery-Vuillemin; Susan Feyerabend; Kurt Miller; Nadine Houédé; Syed Hussain; Elaine Lam; Jonathan Polikoff; Arnulf Stenzl; Paul Mainwaring; David Ramies; Colin Hessel; Aaron Weitzman; Karim Fizazi Journal: J Clin Oncol Date: 2016-07-11 Impact factor: 44.544
Authors: Ayalew Tefferi; Hagop Kantarjian; S Vincent Rajkumar; Lawrence H Baker; Jan L Abkowitz; John W Adamson; Ranjana Hira Advani; James Allison; Karen H Antman; Robert C Bast; John M Bennett; Edward J Benz; Nancy Berliner; Joseph Bertino; Ravi Bhatia; Smita Bhatia; Deepa Bhojwani; Charles D Blanke; Clara D Bloomfield; Linda Bosserman; Hal E Broxmeyer; John C Byrd; Fernando Cabanillas; George Peter Canellos; Bruce A Chabner; Asher Chanan-Khan; Bruce Cheson; Bayard Clarkson; Susan L Cohn; Gerardo Colon-Otero; Jorge Cortes; Steven Coutre; Massimo Cristofanilli; Walter J Curran; George Q Daley; Daniel J DeAngelo; H Joachim Deeg; Lawrence H Einhorn; Harry P Erba; Francisco J Esteva; Elihu Estey; Isaiah J Fidler; James Foran; Stephen Forman; Emil Freireich; Charles Fuchs; James N George; Morie A Gertz; Sergio Giralt; Harvey Golomb; Peter Greenberg; Jordan Gutterman; Robert I Handin; Samuel Hellman; Paulo Marcelo Hoff; Ronald Hoffman; Waun Ki Hong; Mary Horowitz; Gabriel N Hortobagyi; Clifford Hudis; Jean Pierre Issa; Bruce Evan Johnson; Philip W Kantoff; Kenneth Kaushansky; David Khayat; Fadlo R Khuri; Thomas J Kipps; Margaret Kripke; Robert A Kyle; Richard A Larson; Theodore S Lawrence; Ross Levine; Michael P Link; Scott M Lippman; Sagar Lonial; Gary H Lyman; Maurie Markman; John Mendelsohn; Neal J Meropol; Yoav Messinger; Therese M Mulvey; Susan O'Brien; Roman Perez-Soler; Raphael Pollock; Josef Prchal; Oliver Press; Jerald Radich; Kanti Rai; Saul A Rosenberg; Jacob M Rowe; Hope Rugo; Carolyn D Runowicz; Brenda M Sandmaier; Alan Saven; Andrew I Schafer; Charles Schiffer; Mikkael A Sekeres; Richard T Silver; Lillian L Siu; David P Steensma; F Marc Stewart; Wendy Stock; Richard Stone; Rainer Storb; Louise C Strong; Martin S Tallman; Michael Thompson; Naoto T Ueno; Richard A Van Etten; Julie M Vose; Peter H Wiernik; Eric P Winer; Anas Younes; Andrew D Zelenetz; Charles A LeMaistre Journal: Mayo Clin Proc Date: 2015-07-23 Impact factor: 7.616
Authors: A Folch; R C Rostomily; L F Horowitz; A D Rodriguez; Z Dereli-Korkut; R Lin; K Castro; A M Mikheev; R J Monnat Journal: NPJ Precis Oncol Date: 2020-05-19
Authors: A D Rodriguez; L F Horowitz; K Castro; H Kenerson; N Bhattacharjee; G Gandhe; A Raman; R J Monnat; R Yeung; R C Rostomily; A Folch Journal: Lab Chip Date: 2020-04-09 Impact factor: 6.799